Sample signed advisory
A representative, brain-free output — the format a physician receives after submitting a case. Illustrative synthetic patient; decision support only.
CaseTG-EXAMPLE-01 (synthetic)
52 y F · 68 kg · Kidney · Day 133 · ER once-daily · CYP3A5 *3/*3 (non-expresser)
Prior levels: 6.8 · 7.1 · 6.9 ng/mL, all on 4.0 mg/day
TacroGuard recommendation4.5 mg/day
Target trough 5–8 ng/mL · maintenance (>3 months)
✓ cross-check concordant
Genotype
Non-expresser (×1.0) — no genotype-driven dose change
Monitoring
Recheck a pre-dose trough in 2–4 weeks (stable maintenance). Bring forward if renal function, an interacting drug, or the formulation changes.
Why it earns trustThree consecutive troughs are consistent and sit within the maintenance target, so the recommendation is a small, individualised adjustment rather than a change of course. Two independent methods produced the same dose (concordant), which is the built-in agreement check — you can act on the number with confidence. Non-expresser genotype and no interacting co-medication mean there is nothing pulling the estimate away from the measured levels.